## Abstract Knowledge of reβprogramming in cancer cells with metabolic differences from their normal counterparts has resulted in new examination of therapeutic approaches. Several studies of the role of tumor mitochondria in cancer have led to the development of nonβgenotoxic therapies which targe
Targeting mitochondria for cancer therapy
β Scribed by David M. Hockenbery
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 278 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0893-6692
- DOI
- 10.1002/em.20552
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
## Abstract Histone deacetylase (HDAC) is recognized as one of the promising targets for cancer treatment as many HDAC inhibitors have entered clinical trials for both solid and liquid tumors. Nevertheless, the mechanisms underlying the antiproliferative effects of HDAC inhibitors remain elusive. A
## Abstract Tumor progression involves the acquisition of properties which include growthβfactor independent cell proliferation, failure of inhibition by growthβinhibitory signals, ability to invade surrounding tissues, and to evade apoptosis, etc. Characterization of the profile or molecular signa